Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

donepezil hydrochloride/memantine hydrochloride extended release

A fixed combination of the hydrochloride salt form of donepezil and an extended-release (ER) formulation of the hydrochloride salt form of memantine, that may potentially enhance neurocognitive function and may be used for the treatment of Alzheimer's disease. Upon oral administration, donepezil reversibly inhibits acetylcholinesterase. This blocks the hydrolysis of the neurotransmitter acetylcholine, increases its concentration, and enhances cholinergic neurotransmission and function. Memantine, a low to moderate affinity, voltage-dependent, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, binds to and inhibits glutamatergic NMDA receptor-operated cation channels located in the central nervous system (CNS). This prevents the prolonged influx of calcium ions and the associated neuronal excitotoxicity. Donepezil and memantine may improve neurocognitive function in Alzheimer's disease, and may potentially improve neurocognitive function in patients who have received radiation therapy for primary brain tumors or brain metastases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Namzaric
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search